医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Orthocell Appoints Surgical Specialties as Exclusive Distributor

2017年10月11日 AM09:11
このエントリーをはてなブックマークに追加


 

PERTH, Australia

Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has appointed Surgical Specialties Pty Ltd (Surgical Specialties) as its exclusive distributor in Australia and New Zealand for its world leading cell therapies for tendon regeneration (Ortho-ATI®) and cartilage regeneration (Ortho-ACI®).

“Surgical Specialties is a leading distributor of innovative medical devices and one of the few local companies with its own national sales force and marketing teams,” said Managing Director of Orthocell, Paul Anderson. “Surgical Specialties is the ideal partner with established relationships with leading orthopaedic surgeons and sports physicians, a successful track record and a highly skilled and dedicated national sales force,” he added.

Surgical Specialties will take over distribution responsibilities for Orthocell’s cell therapies including targeted promotion activities and initiating sales, as well as assisting with expanding the network of referring doctors and physicians. The exclusive distribution agreement has a term of five years and the arrangement will allow Orthocell to maintain its focus on the development of its novel regenerative medicine products and driving national and international regulatory approvals for its technologies.

“We are very excited to be involved with Orthocell. Orthocell has the only cell therapy intervention listed on the Australian Register of Therapeutic Goods (ARTG) for the repair of damaged or degenerate cartilage in the knee or ankle joint, and an innovative market leading approach for the repair of degenerate tendons. Both products are based on ground-breaking technology and addresses a significant clinical need, particularly in the orthopaedic and sports physician market,” said CEO of Surgical Specialties, Phil Nicholl.

About Surgical Specialties Pty Ltd:

Established in 2006, Surgical Specialties now has a team of over 70 people, with sales offices throughout Australia and New Zealand. Surgical Specialties is an independent distributor of innovative medical devices to the Australian and New Zealand medical community. The business focuses on the following surgical areas: Arthroplasty, Extremities, Specialty Trauma, Orthobiologics, Critical Care and Operating Room Products.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171010006762/en/

CONTACT

General enquiries
Orthocell
Paul Anderson, +61
8 9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor
and Media enquiries

WE Buchan
Ben Walsh, +
61 411 520 012
bwalsh@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆